BR112012009846B8 - método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige - Google Patents

método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige

Info

Publication number
BR112012009846B8
BR112012009846B8 BR112012009846A BR112012009846A BR112012009846B8 BR 112012009846 B8 BR112012009846 B8 BR 112012009846B8 BR 112012009846 A BR112012009846 A BR 112012009846A BR 112012009846 A BR112012009846 A BR 112012009846A BR 112012009846 B8 BR112012009846 B8 BR 112012009846B8
Authority
BR
Brazil
Prior art keywords
ige
drug antibody
isotype anti
detecting
ige isotype
Prior art date
Application number
BR112012009846A
Other languages
English (en)
Other versions
BR112012009846B1 (pt
BR112012009846A2 (pt
Inventor
L Baker Dana
R Nakamura Gerald
B Lowman Henry
Fischer Saloumeh
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR112012009846A2 publication Critical patent/BR112012009846A2/pt
Publication of BR112012009846B1 publication Critical patent/BR112012009846B1/pt
Publication of BR112012009846B8 publication Critical patent/BR112012009846B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

métodos e kits para detecção de um anticorpo antifármaco de isotipo ige, bem como composição para o tratamento de distúrbio mediado por ige. a invenção provê métodos e reagentes úteis para detecção de anticorpos antifármaco de isotipo lge para anticorpos anti-lge terapêuticos e métodos para avaliação do risco de anafilaxia para administração de um anticorpo anti-lge terapêutico.
BR112012009846A 2009-10-26 2010-10-26 método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige BR112012009846B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25505209P 2009-10-26 2009-10-26
US61/255,052 2009-10-26
PCT/US2010/054160 WO2011056606A1 (en) 2009-10-26 2010-10-26 Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis

Publications (3)

Publication Number Publication Date
BR112012009846A2 BR112012009846A2 (pt) 2017-02-21
BR112012009846B1 BR112012009846B1 (pt) 2021-04-20
BR112012009846B8 true BR112012009846B8 (pt) 2021-05-25

Family

ID=43970265

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012009846A BR112012009846B8 (pt) 2009-10-26 2010-10-26 método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige

Country Status (19)

Country Link
US (1) US9315583B2 (pt)
EP (1) EP2494356B1 (pt)
JP (1) JP6139885B2 (pt)
KR (1) KR101832510B1 (pt)
CN (1) CN102695956B (pt)
AU (1) AU2010315470B2 (pt)
BR (1) BR112012009846B8 (pt)
CA (1) CA2778810C (pt)
DK (1) DK2494356T3 (pt)
HK (1) HK1175538A1 (pt)
HU (1) HUE033492T2 (pt)
IL (1) IL219337A (pt)
MX (1) MX344935B (pt)
MY (1) MY182750A (pt)
NZ (1) NZ599600A (pt)
RU (1) RU2642295C2 (pt)
SI (1) SI2494356T1 (pt)
WO (1) WO2011056606A1 (pt)
ZA (1) ZA201202999B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5656853B2 (ja) 2008-10-27 2015-01-21 ジェナリーテ， インコーポレイテッド 光学的な探査及び検知に基づくバイオセンサ
US9696305B2 (en) 2011-10-31 2017-07-04 Bloodworks Antibody response phenotyping
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
DK3084439T3 (en) * 2013-12-20 2018-12-03 Phadia Ab ANALYSIS OF ANTIBODIES
KR102224649B1 (ko) * 2014-11-14 2021-03-05 바이오메리카인코포레이티드 Ibs 민감도 테스트 구성, 장치 및 방법
TWI691512B (zh) 2015-02-20 2020-04-21 日商橘生藥品工業股份有限公司 Ｆｃ融合高親和性ＩｇＥ受體α鏈
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
KR101957411B1 (ko) 2017-09-13 2019-03-12 (주)뷰티화장품 생약 추출물 함포 펙틴 마이크로캡슐을 포함하는 피부 개선용 화장료 조성물
TWI737955B (zh) * 2018-01-12 2021-09-01 南韓商Ｇｉ創新股份有限公司 包含益生菌及IgE結合多肽的組成物及其用途
US20210231651A1 (en) * 2018-04-30 2021-07-29 Genalyte, Inc. Methods and compositions for point of care measurement of the bioavailability of therapeutic biologics
WO2020172496A1 (en) * 2019-02-21 2020-08-27 Ding Qinxue Method of removing non-specific binding signals using microparticles
BR112022000246A2 (pt) * 2019-07-08 2022-02-22 Gi Innovation Inc Dímero polipeptídico com elevado teor de ácido siálico, compreendendo o domínio extracelular da subunidade alfa do receptor fc de ige e composição farmacêutica compreendendo o mesmo
CN112285351A (zh) * 2019-07-22 2021-01-29 上海益诺思生物技术股份有限公司 一种抗IgE单抗的ELISA检测方法
CN110358738B (zh) * 2019-08-22 2021-08-13 中国食品药品检定研究院 一种稳定测定抗IgE抗体药物生物学活性的方法
EP4229391A1 (en) * 2020-10-14 2023-08-23 I-Mab Biopharma Co., Ltd. Methods for mitigating interference by therapeutic anti-cd47 antibodies in pre-transfusion assays
JP7062803B1 (ja) * 2021-03-31 2022-05-06 積水メディカル株式会社 抗薬物抗体測定方法
CN114047343B (zh) * 2022-01-13 2022-05-31 美迪西普亚医药科技(上海)有限公司 双耐受型抗IgE单抗药物的免疫原性分析试剂盒及其使用方法和应用
CN116699147A (zh) * 2023-08-04 2023-09-05 军科正源（北京）药物研究有限责任公司 检测总IgE含量的方法以及相关试剂盒

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (pt) 1967-05-23 1971-08-02 Pharmacia Ab
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
DE2031216A1 (de) 1969-06-19 1971-01-14 Citizen Watch Co Ltd , Tokio Tag und Datum Stellvorrichtung fur Uhren mit Kalender
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4459359A (en) * 1981-11-19 1984-07-10 New York Blood Center, Inc. Sensitive immunoassays of antigens or antibodies sequestered within immune complexes
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4683136A (en) * 1985-03-06 1987-07-28 Scripps Clinic And Research Foundation Proteinaceous antigens with conformation-independent and conformation-dependent determinants
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992017207A1 (en) 1991-03-26 1992-10-15 Tanox Biosystems, Inc. MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS
JPH0772150A (ja) * 1993-09-02 1995-03-17 Tonen Corp ＩｇＥの測定方法
KR20050085971A (ko) 1995-04-27 2005-08-29 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
DE69840334D1 (de) * 1997-09-22 2009-01-22 Novartis Vaccines & Diagnostic Puffern zur stabilizierung von hcv antigenen
WO2002030463A2 (en) 2000-10-12 2002-04-18 Genentech, Inc. Reduced-viscosity concentrated protein formulations
EP1527099A2 (en) * 2002-08-01 2005-05-04 Northwestern University Mutants of ige proteins and uses thereof
CN1829806A (zh) 2003-02-01 2006-09-06 唐纳士公司 产生高亲和力抗体的方法
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
EP1610820B2 (en) 2003-04-04 2013-08-21 Genentech, Inc. High concentration antibody and protein formulations
ES2340767T5 (es) * 2004-07-01 2013-11-13 Biomay Ag Alérgenos de ácaros del polvo doméstico
AU2005282720B2 (en) * 2004-09-02 2011-08-04 Genentech, Inc. Anti-FC-gamma RIIB receptor antibody and uses therefor
DE602005015981D1 (de) * 2005-10-17 2009-09-24 Pls Design Gmbh Chimäre zwischen einer alpha-Kette eines humanen IgE Rezeptor und konstanten Immunoglobulin-Domänen von Vögeln zur Determination von Serum IgE.
US20070184501A1 (en) * 2006-02-07 2007-08-09 Beckman Coulter, Inc. Blocker reagent for reduction of heterophile interferences
WO2008028068A2 (en) * 2006-08-30 2008-03-06 Genentech, Inc. NON-HUMAN PRIMATE FCεR1α POLYPEPTIDES

Also Published As

Publication number Publication date
IL219337A0 (en) 2012-06-28
MY182750A (en) 2021-02-05
EP2494356A1 (en) 2012-09-05
MX2012004833A (es) 2012-07-04
RU2642295C2 (ru) 2018-01-24
MX344935B (es) 2017-01-11
JP2013508740A (ja) 2013-03-07
NZ599600A (en) 2015-04-24
RU2012121559A (ru) 2013-12-10
CA2778810A1 (en) 2011-05-12
BR112012009846B1 (pt) 2021-04-20
AU2010315470B2 (en) 2016-05-05
US20110183363A1 (en) 2011-07-28
EP2494356A4 (en) 2013-07-03
CN102695956B (zh) 2015-12-09
KR101832510B1 (ko) 2018-02-26
SI2494356T1 (sl) 2017-07-31
BR112012009846A2 (pt) 2017-02-21
HK1175538A1 (zh) 2013-07-05
IL219337A (en) 2017-06-29
WO2011056606A1 (en) 2011-05-12
WO2011056606A8 (en) 2012-05-18
US9315583B2 (en) 2016-04-19
ZA201202999B (en) 2013-06-26
CN102695956A (zh) 2012-09-26
KR20120116400A (ko) 2012-10-22
AU2010315470A1 (en) 2012-05-24
CA2778810C (en) 2018-09-04
JP6139885B2 (ja) 2017-05-31
EP2494356B1 (en) 2017-03-15
HUE033492T2 (en) 2017-12-28
DK2494356T3 (en) 2017-05-15

Similar Documents

Publication Publication Date Title
BR112012009846B8 (pt) método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige
BR112015014751A2 (pt) anticorpos anti-tau humanos
EA201190041A1 (ru) Человеческие аутоантитела против альфа-синуклеина
CR20110118A (es) Tratamiento de enfermedades autoinmunes e inflamatorias
HN2008001104A (es) Compuestos para anticuerpos de dickpf-1 y70-4
BRPI0907135B8 (pt) uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
CO7151488A2 (es) Anticuerpos de reacción cruzada anti-jagged1/jagged 2, anticuerpos anti-jagged activables y métodos de uso de los mismos
EA201490825A1 (ru) Tdp-43-специфически связывающие молекулы
MY157173A (en) Modified humanised anti-interleukin-18
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
ECSP13012525A (es) Anticuerpos contra metaloproteasa-9 de matriz.
EA200870185A1 (ru) Комбинации ингибиторов ang2 и vegf
CR20120086A (es) Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana
CU24058B1 (es) Antagonistas de pcsk9
GT201300149A (es) Proteinas de union al tnf-a
EA201370081A1 (ru) Антитела к cd48 и их применение
EA201591131A1 (ru) Днк-конструкции антитела и способ их применения
CL2007003622A1 (es) Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
AR059867A1 (es) Anticuerpos para la htslp
BR112013024574A2 (pt) polipeptídeo, uso, método de tratamento de indivíduos portadores de doenças e método de tratamento de indivíduos que possuem doenças com um polipeptídeo
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
BRPI1013688A8 (pt) Proteínas de ligação de il-17.
CO6280500A2 (es) Anticuerpos humanizados especificos pare l factor von willebrand
BR112013021350A2 (pt) anticorpo e antígeno reconhecido de células iniciadoras de tumor e o uso destes
BRPI0518209A (pt) agentes de ligação especìficos à angiopoietina-2

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/10/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/10/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF